Tekmira Provides Periodic Update to Litigation
17 janv. 2012 16h32 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Jan. 17, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, disclosed that...
Tekmira Granted an Injunction Against Certain Individuals From AlCana Technologies by the Supreme Court of British Columbia
10 janv. 2012 16h30 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Jan. 10, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, disclosed today...
Tekmira's LNP Technology Enables Alnylam's Positive ALN-PCS Clinical Data
04 janv. 2012 16h03 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Jan. 4, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today reported...
Tekmira Provides Periodic Update to Litigation
21 déc. 2011 17h30 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Dec. 21, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today provided...
Tekmira Secures $3 Million Financing
21 déc. 2011 16h50 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Dec. 21, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced it...
Tekmira Pharmaceuticals Receives Approval from FDA to Initiate TKM-Ebola Phase 1 Clinical Trial
28 nov. 2011 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 28, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX: TKM), a leading developer of RNA interference (RNAi) therapeutics, announced...
Tekmira's LNP Technology Enables Alnylam's ALN-TTR01 Clinical Data
21 nov. 2011 08h34 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 21, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR)(TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today reported...
Tekmira Files for an Injunction in the Supreme Court of British Columbia Seeking Return of Confidential Documents
16 nov. 2011 08h30 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 16, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, disclosed today...
Tekmira Provides Corporate Update and Announces Third Quarter 2011 Results
08 nov. 2011 16h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 8, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced its...
Tekmira Conference Call and Webcast Advisory: Third Quarter 2011 Operating Results and Corporate Update
03 nov. 2011 16h30 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 3, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that...